Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun 7:15:1045-1049.
doi: 10.2147/CCID.S363321. eCollection 2022.

Causes of Botulinum Toxin Treatment Failure

Valentina Shtefan  1 , James Fletcher  2 , Olga Anna Duclos  3
Affiliations
Review

Causes of Botulinum Toxin Treatment Failure

Valentina Shtefan et al. Clin Cosmet Investig Dermatol. .

Abstract

Purpose: The purpose of this article is to review the cause of botulinum toxin (BT) failure and determine the ways to minimize the risks of its occurrence.

Methods: A PubMed and Google Scholar literature search was conducted with the search terms botulinum toxin, treatment, failure, causes, and prevention. Fifteen relevant articles were found and used as the scientific base for this article.

Results: The failure of BT therapy is associated with immunogenic and non-immunogenic causes and the formation of neutralizing antibodies toward the active components of BT or the complexing proteins. Enzyme-linked immunosorbent assay (ELISA) testing and mouse hemidiaphragm assay (MHA) can diagnose the failure. The risk of developing treatment failure can be minimized by using complexing protein-free formulations, selecting a treatment regimen with the least immunogenicity, proper injection technique, and gentle product handling.

Conclusion: The treatment failure can compromise the success of BT treatment. Current medical literature shows controversial evidence for and against BT immunogenicity. Therefore, the cause of BT failure is likely to be multifactorial.

Keywords: botulinum toxin; causes; immunogenicity; treatment failure.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Similar articles

See all similar articles

Cited by

References

    1. Dutton JJ, Fowler AM. Botulinum toxin in ophthalmology. Surv Ophthalmol. 2007;52(1):13–31. doi:10.1016/j.survophthal.2006.10.003 - DOI - PubMed
    1. Giordano CN, Matarasso SL, Ozog DM. Injectable and topical neurotoxins in dermatology: indications, adverse events, and controversies. J Am Acad Dermatol. 2017;76(6):1027–1042. doi:10.1016/j.jaad.2016.11.012 - DOI - PubMed
    1. Aesthetic plastic surgery national databank statistics 2019. The Aesthetic Society Web site. Available from: http://www.surgery.org. Accessed November 23, 2020.
    1. Samizadeh S, De Boulle K. Botulinum neurotoxin formulations: overcoming the confusion. Clin Cosmet Investig Dermatol. 2018;11:273–287. doi:10.2147/CCID.S156851 - DOI - PMC - PubMed
    1. Hanna E, Pon K. Updates on botulinum neurotoxins in dermatology. Am J Clin Dermatol. 2020;21(2):157–162. doi:10.1007/s40257-019-00482-2 - DOI - PubMed